8 results about "Clostridium botulinum" patented technology

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

A composition comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a plurality of variant species, wherein the variant species comprises BoNT / A with a C-terminal trunca

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly to a culture medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a Clostridium botulinum strain is cultured using a culture medium comprising vegetable peptone, glucose, and yeast extract without animal-derived components, the growth rate of the strain is increased compared to existing culture media, and the strain can be safely cultured since animal-derived components are not included, thereby increasing the yield of botulinum toxin.

Shelf-stable packaged low acid-beverages and methods for the same are disclosed. The shelf-stable packaged low acid beverage may include a container and a liquid low acid beverage disposed and sealed in the container. The liquid low acid beverage may include oxygen dissolved therein in an amount sufficient to prevent growth of bacteria, such as Clostridium botulinum or other bacteria such as Psychotrophs or lactic bacteria. The method may include dissolving the liquid low acid beverage into the container, dissolving oxygen and / or nitrogen into the low liquid beverage disposed in the container, and sealing the container. The container and the liquid low acid beverage may define a headspace disposed in the container. The oxygen may be present in the headspace in an amount greater than 0%, or greater than or equal to about 12%, based on the volume of the headspace.

The present invention relates to the technical field of a method for preparing a recombinant botulinum toxin type A, and particularly relates to a botulinum toxin type A obtained by means of gene recombination technology, the amino acid sequence of which is identical to the sequence of botulinum toxin type A prepared by means of extraction and purification from a wild Clostridium botulinum strain. Provided is a single-chain protein of botulinum toxin type A, sequentially comprising: a light chain of botulinum toxin type A or a modified light chain of botulinum toxin type A, a linking region, and a heavy chain of botulinum toxin type A. The single-chain protein is subjected to fermentation, crude purification, enzyme digestion, and fine purification to obtain high-quality recombinant botulinum toxin type A. The present invention can solve the existing problems of complex process, long period, high safety risk and the like in the preparation of botulinum toxin type A by using wild Clostridium botulinum strains, and also solve the existing problem that the amino acid sequence of botulinum toxin type A prepared by means of gene recombination technology cannot be identical to that of botulinum toxin type A prepared by wild Clostridium botulinum strains.

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.

The present application relates to the preparation method of type A recombinant botulinum toxin technical field, specifically relates to the type A botulinum toxin obtained by gene recombination technology, the amino acid sequence is identical with the sequence of type A botulinum toxin prepared by wild strain Clostridium botulinum extraction and purification.The technical scheme provides a single chain protein of type A botulinum toxin, which comprises in sequence: type A botulinum toxin light chain or modified type A botulinum toxin light chain, connecting region, type A botulinum toxin heavy chain.The single chain protein of the scheme is obtained after fermentation, crude purification, enzyme cutting and fine purification High-quality recombinant type A botulinum toxin.The technical scheme can solve the problems of complex process, long cycle, high safety risk and the like of the existing type A botulinum toxin prepared by wild strain Clostridium botulinum, and solve the problem that the existing gene recombination technology cannot obtain the amino acid sequence identical with the type A botulinum toxin prepared by wild strain Clostridium botulinum.

The invention discloses a clostridium botulinum neurotoxin A receptor binding structural domain mutant with high affinity, and compared with a wild type clostridium botulinum neurotoxin A receptor binding structural domain, the clostridium botulinum neurotoxin A receptor binding structural domain mutant has any one of the following amino acid mutation sites: P1139S, L1154A, G1157L, R1140H, I1148N, L1154G, L1154Y, S1153G and Y1165W. The affinity of the botulinum neurotoxin A receptor binding domain mutant and a receptor SV2 is remarkably higher than that of a wild type, and the mutant and recombinant protein have wide application prospects in the fields of drug delivery, neurological disease treatment, biological detection and the like.